Ariceum Therapeutics and AmbioPharm enter into strategic manufacturing and supply partnership

BERLIN & NORTH AUGUSTA, SC–()–Ariceum Therapeutics (Ariceum), a private biotechnology company developing radiopharmaceuticals for diagnostics and targeted systemic radiation therapy for certain difficult-to-treat cancers, and AmbioPharm, a global peptide contract development and manufacturing organization, today announce that they have entered into a strategic partnership to manufacture and supply peptide conjugates to be used by Ariceum in future clinical studies.

AmbioPharm is supporting Ariceum with cGMP manufacturing and supply of peptide conjugates that will be radiolabeled as a radiopharmaceutical end product used in upcoming clinical trials. Radiolabeled receptor-binding peptides are an important class of radiopharmaceuticals for the targeted diagnosis and treatment of tumors and will be used in clinical trials for Ariceum’s lead radiopharmaceutical, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive and difficult to treat cancers. cancers, currently in Phase I/II. Satoreotide is being developed as a “theranostic” couple for the combined diagnosis and targeted radionuclide treatment of these tumours.

As a peptide contract development and manufacturing organization (CDMO) providing cGMP peptide APIs with capabilities ranging from research to commercial scales, AmbioPharm actively engages with innovative biopharmaceutical companies in the development of technologies first-in-class, breakthrough peptides that utilize AmbioPharm’s peptide manufacturing expertise and deep scientific background in novel and conventional peptide chemistry.

Manfred Rüdiger, PhD, CEO of Ariceum Therapeutics, said: “Ariceum is very pleased to partner with AmbioPharm. As we build our platform and continue to advance our lead product, satoreotide, into clinical trials, we are delighted to be supported by such an established and trusted manufacturer of high quality, FDA inspected peptide APIs. .

Michael W. Pennington, PhD, Chief Scientific Officer at AmbioPharm, added: “We are excited to play a role in the synthesis of this ‘theranostic’ peptide which will be a valuable resource for the treatment and diagnosis of certain difficult-to-treat neuroendocrine cancers. »

Notes to Editors

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical-stage radiopharmaceutical company focused on the precision diagnosis and treatment of certain neuroendocrine cancers and other aggressive, difficult-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium were huge contributions to the search for cancer treatments. Ariceum’s primary targeted systemic radiopharmaceutical, 177Lu-satoreotide tetraxetan (“Satoreotide”) is a somatostatin type 2 antagonist (SST2) receptor that is overexpressed in neuroendocrine tumors (NET), some aggressive cancers such as small cell lung cancer (SCLC), and childhood cancer, neuroblastoma, all of which have few treatment options and bad predictions. Satoreotide is being developed as a “theranostic” couple for the combined diagnosis and targeted radionuclide treatment of these tumours.

Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ariceum is headquartered in Berlin, with operations in Germany and activities currently in Europe, North America and Australia.

Ariceum is led by a highly experienced management team and backed by specialist investors including EQT Life Sciences (formerly LSP), HealthCap and Pureos Bioventures. For more information, please visit www.ariceum-therapeutics.com

About AmbioPharm

AmbioPharm is a leading, innovation-driven company specializing in the development and manufacturing of peptides and peptide-related products. With a full range of services, AmbioPharm manufactures customized products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide. Further information is available at www.ambiopharm.com.

Source link

About Cecil D. Ramirez

Check Also

New era startups boost the supply chain

Mowito Robotics, Tusker, Sytlumia, Raaho, Conmove and Celcius Logistics are working on the digitalization of …